Tapentadol prolonged release for severe chronic osteoarthritis pain in the elderly: improvements in daily functioning and quality of life.

Abstract

Background: Chronic osteoarthritis (OA) pain leads to severe impairments in physical functioning and quality of life. Patients & methods: Data of patients with severe chronic knee and/or hip OA pain were extracted from the database of a prospective, noninterventional trial to assess the benefits of tapentadol prolonged release (PR) in elderly patients (>65 years of age; n = 1162) compared with younger patients (≤65 years of age; n = 498). Results: Tapentadol PR treatment (up to 3 months) significantly reduced pain intensity and pain-related restrictions on daily functioning and significantly improved physical and mental quality of life in both patient groups. The incidence of adverse drug reactions was low. Conclusion: Tapentadol PR is a useful strong analgesic to improve pain intensity, physical functioning and quality of life in elderly OA patients.

• Authors: Kai-Uwe Kern, Melanie Sohns, Birgit Heckes, Christian Elling
• Journal: Pain management (Pain Manag) Vol. 10 Issue 2 Pg. 85-95 (Mar 2020) ISSN: 1758-1877 [Electronic] England
• PMID: 31973627 (Publication Type: Journal Article)

Chemical References

• Analgesics, Opioid
• Delayed-Action Preparations
• Tapentadol

Topics

• Activities of Daily Living
• Aged
• Aged, 80 and over
• Analgesics, Opioid (administration & dosage, pharmacology)
• Chronic Pain (drug therapy, etiology)
• Delayed-Action Preparations
• Female
• Humans
• Male
• Musculoskeletal Pain (drug therapy, etiology)
• Osteoarthritis, Hip (complications)
• Osteoarthritis, Knee (complications)
• Outcome Assessment, Health Care
• Quality of Life
• Tapentadol (administration & dosage, pharmacology)